AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27927048
Drug: BTDS 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTDS 10 mcg/h
Trial: 27927048
Drug: BTDS 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTDS 40 mcg/h
Trial: 27927048
Drug: BTDS 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTDS 80 mcg/h
Trial: 25210019
Drug: Targeted albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted albendazole therapy (n = 467)
Trial: 25210019
Drug: Nontargeted albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nontargeted albendazole therapy (n = 513)
Trial: 25210019
Drug: Albendazole therapy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole therapy (both targeted and nontargeted)
Trial: 23471702
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of amlodipine, telmisartan, and hydrochlorothiazide
Trial: 9112303
Drug: Sit up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit up and take 20 deep breaths on 10 occasions daily (group B)
Trial: 9112303
Drug: Sit up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sit up and blow bubbles in a bottle containing 10 cm water through a plastic tube 20 times on 10 occasions daily (group C)
Trial: 3322828
Drug: Digoxin marker
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin marker in capsules of gemfibrozil (4.4 micrograms twice a day)
Trial: 3322828
Drug: Digoxin marker
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin marker in capsules of placebo (4.4 micrograms twice a day)
Trial: 31537375
Drug: Dilute betadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute betadine (0.02% solution) added to sterile water (SW) splash basin
Trial: 21575102
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg·kg(‐1)
Trial: 21575102
Drug: Dexmedetomidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 2 μg·kg(‐1)
Trial: 21575102
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 μg·kg(‐1)
Trial: 21575102
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (acetaminophen as needed)
Trial: 18470742
Drug: Multiple channel
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple channel exposure therapy (M-CET)
Trial: 16782927
Drug: Carboplatin and
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin and cisplatin (CC)
Trial: 9926970
Drug: Pamidronate 60
RxNorm normalized name: pamidronate 60 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 60 mg i.v. every 3 weeks for a maximum of six cycles
Trial: 9926970
Drug: Pamidronate 90
RxNorm normalized name: pamidronate 90 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate 90 mg i.v. every 3 weeks for a maximum of six cycles
Trial: 10843163
Drug: Pamidronate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate treatment
Trial: 10739358
Drug: Average monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Average monthly direct costs during treatment phase
Trial: 10739358
Drug: Average monthly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Average monthly direct costs during follow-up
Trial: 9176830
Drug: 1.25 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 g/day DHA
Trial: 9176830
Drug: 2.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g/day DHA
Trial: 1412606
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 200 mg of labetalol
Trial: 1412606
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of 0.5 mg/kg of labetalol
Trial: 30861510
Drug: Vaginal suppositories
RxNorm normalized name: Miconazole Nitrate Vaginal Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal suppositories containing low‐molecular‐weight hyaluronic acid (HA) from day 1 of radiotherapy for 5 weeks.
Trial: 26972955
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy plus pravastatin
Trial: 20942575
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (combination of antioxidants extracted from fruit, berries, and vegetables) for 12 weeks
Trial: 10357412
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with monitoring using [technetium 99m]-sestamibi (MIBI) scintimammography
Trial: 7497759
Drug: Normothermic CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normothermic CPB (n = 19, rectal temperature: 35.9 ± 0.1 degrees C)
Trial: 7497759
Drug: Hypothermic CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothermic CPB (n = 19, rectal temperature: 29.2 ± 0.5 degrees C)
Trial: 2149508
Drug: Goserelin (Zoladex)
RxNorm normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin (Zoladex) 3.6 mg depot preparation combined with flutamide (Eulexin) 250 mg t.i.d.
Trial: 6997516
Drug: Seven-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-day regimen of metronidazole (250 mg three times daily)
Trial: 22126349
Drug: Fluoride chewing
RxNorm normalized name: sodium fluoride Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride chewing gum (FCG: 50 μg fluoride)
Trial: 18174269
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1.2 g/day for 2 days
Trial: 18174269
Drug: Zinc (Zn)
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc (Zn) 60 mg/day for 1 day
Trial: 17023703
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein with native phytate (40 g/d)
Trial: 9822499
Drug: Daily aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily aspirin (60 mg)
Trial: 2698360
Drug: Trabeculectomy at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabeculectomy at diagnosis followed by supplementary medical therapy if necessary
Trial: 2698360
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management of medical therapy followed by trabeculectomy in unsuccessful cases
Trial: 4876730
Drug: Therapeutic trial
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic trial treatment
Trial: 4876730
Drug: Earlier trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Earlier trial treatment in Morocco
Trial: 31369613
Drug: Motor control
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor control (low‐dose exercise) and manual therapy
Trial: 31369613
Drug: General strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General strength and conditioning training (moderate‐dose exercise)
Trial: 17786128
Drug: TDM-directed dose
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDM-directed dose modifications
Trial: 14681839
Drug: Copper supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper supplementation (3 mg copper/d as copper-glycinate) for 6 weeks
Trial: 14681839
Drug: Copper supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper supplementation (3 mg copper/d as copper-glycinate) plus zinc supplementation (30 mg zinc/d as zinc-glycinate) for 6 weeks
Trial: 9449404
Drug: Potassium 40
RxNorm normalized name: penicillin G potassium 400000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium 40 mmol, Calcium 30 mmol (1200 mg), Magnesium 14 mmol (336 mg)
Trial: 9449404
Drug: Calcium 30
RxNorm normalized name: CALCIUM 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 30 mmol (1200 mg)
Trial: 9449404
Drug: Magnesium 14
RxNorm normalized name: Calcium/Gelatin/Magnesium 144 MG-324 MG-140 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium 14 mmol (336 mg)
Trial: 7616978
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (1.9 mg/mL) plus droperidol (0.125 mg/mL)
Trial: 7616978
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate (2 mg/mL)
Trial: 2374275
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid (1.5 g three times daily)
Trial: 31409606
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg once daily for 8 weeks
Trial: 31409606
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg once daily for 2 weeks
Trial: 31409606
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 2 weeks
Trial: 31409606
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg once daily for 4 weeks
Trial: 31409606
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg once daily for 2 weeks (baseline LA grade C/D)
Trial: 31409606
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 2 weeks (baseline LA grade C/D)
Trial: 31409606
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg once daily for 4 weeks (baseline LA grade C/D)
Trial: 31409606
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 4 weeks (baseline LA grade C/D)
Trial: 31409606
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg once daily for 8 weeks (baseline LA grade C/D)
Trial: 31409606
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg once daily for 8 weeks (baseline LA grade C/D)
Trial: 21429025
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine (DEX) - i.v. infusion of 3.0 µg/kg per h over 5 min followed by continuous infusion at 0.4 µg/kg per h (n = 30)
Trial: 15253399
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg elemental iron daily
Trial: 15253399
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg elemental iron weekly
Trial: 11226079
Drug: HES 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4 (2430 +/- 310 mL administered until the morning of the first postoperative day)
Trial: 11226079
Drug: Gelatin (2830
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin (2830 +/- 350 mL administered until the morning of the first postoperative day)
Trial: 2655967
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (mexiletine, pirmenol, procainamide, propafenone, quinidine, sotalol)
Trial: 26868469
Drug: 5% amlexanox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% amlexanox (lexanox 5% oral paste)
Trial: 25796693
Drug: Longbishu Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longbishu Capsule combined with mesylate doxazosin
Trial: 20001867
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with paclitaxel or docetaxel
Trial: 10383538
Drug: Inhaled (INH)
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled (INH) 20 mg sodium cromoglycate
Trial: 10383538
Drug: Inhaled +
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled + oral charcoal (INHC) 20 mg sodium cromoglycate
Trial: 10383538
Drug: Oral (ORAL)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (ORAL) 20 mg sodium cromoglycate
Trial: 10383538
Drug: Oral +
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral + oral charcoal (ORALC) 20 mg sodium cromoglycate
Trial: 8983611
Drug: Bupivacaine (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (total of 20 ml, 0.25 per cent) injected into the subcutaneous periportal tissue and periportal parietal peritoneal injection of bupivacaine (total of 20 ml, 0.25 per cent)
Trial: 8983611
Drug: Standard technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard technique with bupivacaine (total of 20 ml, 0.5 per cent) injected into the subcutaneous periportal tissue
Trial: 1840158
Drug: ciclopiroxolamine (cic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciclopiroxolamine (cic) cream
Trial: 7055343
Drug: Fenoterol (Berotec)
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (Berotec) delivered as inhalation powder
Trial: 31126258
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab (T)
Trial: 31126258
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab (T) plus pertuzumab (P)
Trial: 24038152
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg QW
Trial: 23587455
Drug: Intravenous parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Intravenous parecoxib at a dose of 40 mg followed by 40 mg every 12 h for 48 h (Group P)
Trial: 20459801
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous infusion of furosemide, titrated to urine output
Trial: 16629791
Drug: Salt chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salt chamber treatment (active group)
Trial: 11185635
Drug: Telmisartan 120
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 120 mg administered between dialyses
Trial: 11185635
Drug: Telmisartan 120
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telmisartan 120 mg administered during dialysis
Trial: 8866807
Drug: qd SSKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qd SSKI (one daily dose)
Trial: 8866807
Drug: tid SSKI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tid SSKI (three daily doses)
Trial: 8499751
Drug: Pseudomonas hyperimmunoglobulin
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas hyperimmunoglobulin (Psomaglobin N) 250 mg/kg on days 3, 5, 7, 10, and 13
Trial: 8499751
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups with inhalation injury
Trial: 31563889
Drug: Multiple passes
RxNorm normalized name: MED PASS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple passes or rescue treatment
Trial: 30264120
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy with intravenous ertapenem for 3 days followed by 7 days of oral levofloxacin and metronidazole
Trial: 25011647
Drug: 10 grams
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 grams of prebiotic (inulin/oligofructose) daily for 12 weeks
Trial: 25011647
Drug: 10 grams
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 grams placebo (maltodextrin) daily for 12 weeks
Trial: 22138360
Drug: Fermented sea
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented sea tangle (FST) 1.5 g/day for 4 weeks
Trial: 17335309
Drug: Medication Events
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Medication Events Monitoring System (MEMS)
Trial: 10448449
Drug: Mianserin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (15 mg/day)
Trial: 9038524
Drug: Mild stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild stimulant laxative (Dulcolax)
Trial: 9038524
Drug: Osmotic laxative
RxNorm normalized name: HYPEROSMOTIC LAXATIVES
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic laxative (Citramag)
Trial: 29396845
Drug: Multiple-choice test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-choice test with genotypes LG, VE, J, MG, MOP, HS-20, VA, MT
Trial: 27103607
Drug: Biologic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic therapies targeting immunoglobulin E (IgE) and interleukin (IL)-5 pathways in CRSwNP patients.
Trial: 27103607
Drug: Biologic therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic therapies targeting the IL-4/IL-13 pathway and other type 2 inflammatory pathways in CRSwNP patients.
Trial: 24292155
Drug: Q-switched Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q-switched Nd:YAG laser plus Er:YAG micropeel (combined therapy)
Trial: 21442171
Drug: 12-week supervised
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week supervised training programme consisting of 3 weekly sessions of aerobic, strengthening and flexibility exercises
Trial: 15845756
Drug: Lamotrigine (LTG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG, 100 mg-400 mg/day, mean modal dose 240 mg)
Trial: 15845756
Drug: Lithium (Li,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (Li, 0.8 mEq/L-1.1 mEq/L, mean modal dose 750 mg)
Trial: 7622805
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine (NE) reuptake inhibitors
Trial: 7622805
Drug: Mixed NE/serotonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed NE/serotonin reuptake inhibitors
Trial: 17557453
Drug: eszopiclone 3
RxNorm normalized name: eszopiclone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eszopiclone 3 mg (cotherapy)
Trial: 17557453
Drug: placebo (monotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (monotherapy)
Trial: 15805382
Drug: Standard 2-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 2-dose regimen of TIV administered in the fall
Trial: 15805382
Drug: Early schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early schedule of a single spring dose followed by a fall dose of TIV
Trial: 15805382
Drug: TIV with
RxNorm normalized name: AEROSOL POWDER, BREATH ACTIV WITH SENSOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIV with concomitant vaccines
Trial: 12087544
Drug: Bleaching treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching treatments (various concentrations) for 7 or 14 days
Trial: 12087544
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (water instead of bleaching gel)
Trial: 2694604
Drug: 250, 500,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250, 500, or 1,000 mg/kg of IVIG plus antibiotics
Trial: 820104
Drug: Nitroglycerin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (5 mg)
Trial: 28030534
Drug: Patients off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients off steroids
Trial: 21563503
Drug: Jingyuankang capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jingyuankang capsule
Trial: 21563503
Drug: Leucogen tablet
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Leucogen tablet
Trial: 19290019
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment
Trial: 11242482
Drug: Modified sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified sham feeding a low-fat meal (6 g fat)